Another attractive therapeutic approach is triple therapy (anti‐PD1/PD‐L1+anti‐CTLA4+oncolytic viruses), which effectively activates immune memory and inhibits cancer recurrence more than dual therapy.[165] An investigation used triple therapy by combining oncolytic adenoviruses with anti‐PD‐L1 and anti‐CTLA4. This evidence concerns the gene CD274 and cancer.